Search clinical trials for: Edetate Disodium

Total 12615 results

Jonsson Comprehensive Cancer Center

No longer available

C11 Sodium Acetate PET/CT Imaging of PCa

Prostate Cancer

United States
Wendell Yap, MD
University of Kansas Medical Center

No longer available

Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan

Prostate Cancer

United States
Phoenix Molecular Imaging

Completed

PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma

Prostate Cancer

United States
National Institute of Neurological Disorders and...

Completed

Gene Therapy for the Treatment of Brain Tumors

Neoplasm Metastasis | Brain Neoplasm

United States
Aga Khan University
Zeenat Qureshi Stroke Institute

Recruiting

Best Solution Identification to Prevent Hyperchloremia Combinations of Sodium Chloride and Sodium Acetate IV Fluids Along With Standard of Care Treatment in Acute Stroke Patients (sodium acetate)

Stroke, Acute

Pakistan
Phoenix Molecular Imaging

Withdrawn

C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression

Gliomas

United States
M.D. Anderson Cancer Center

Recruiting

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome and other conditions

United States
Rigel Pharmaceuticals

Completed

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

T Cell Lymphoma

United States, Canada
Phoenix Molecular Imaging

Completed

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Prostate Cancer | Prostate Adenocarcinoma

United States
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder
Sunovion

Completed

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

Epilepsy

United States, Bulgaria, Czech Republic, Serbia, Ukraine
Bial - Portela C S.A.

Terminated

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

BIPOLAR I DISORDER
Cytonet GmbH & Co. KG

Completed

Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment

Urea Cycle Disorders

Germany
University Hospital, Basel, Switzerland

Completed

Oral Glucosestimulation After Gastric Bypass Surgery

Obesity

Switzerland
Federal University of São Paulo

Completed

Fluid Therapy During Brain Tumor Resection in Children

Brain Neoplasms

Brazil
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
Bial - Portela C S.A.

Completed

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Partial Epilepsy

Portugal
Peking Union Medical College Hospital

Not yet recruiting

Effect of Balanced Saline Solution and Albumin on Volume Expansion in Shock Patients

Shock
Centre Hospitalier Saint Joseph Saint Luc de Lyon

Unknown

ZEBinix® Retention Rate in Epilepsy in Elderly Patients (ZEBRE)

Epilepsy | Aging | Epilepsy; Seizure | Aging Disorder

France
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Refractory Partial Epilepsy

Portugal
Eisai Inc.

Completed

A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)

Partial Onset Seizures

France, United Kingdom, Germany, Denmark, Czech Republic, Norway, Sweden, Ireland
Bial - Portela C S.A.
Sunovion

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Partial Epilepsy

United States, Argentina, Germany, France, Belgium, Canada, Italy, Poland, Greece, Brazil, Cyprus
Bial - Portela C S.A.

Completed

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Epilepsy

Romania
Bial - Portela C S.A.

Completed

An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Emory University

Completed

A Low ChloridE hyperTonic Solution for Brain Edema (ACETATE)

Acute Kidney Injury | Subarachnoid Hemorrhage

United States
Bial - Portela C S.A.

Completed

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Epilepsy
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

Partial Epilepsy

Netherlands, Poland, Italy, Russian Federation, Ukraine
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
University of Washington
Fred Hutchinson Cancer Center

Withdrawn

The Role of GLP-1 in Satiety Perception in Humans

Obesity | Appetite Regulation

United States
Bial - Portela C S.A.

Completed

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

Epilepsy
Cytonet GmbH & Co. KG
CRS Clinical Research Services Mannheim GmbH

Completed

Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function

Urea Cycle Disorders

Germany
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Epilepsy
Bial - Portela C S.A.

Completed

A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

Epilepsy

United Kingdom
First Affiliated Hospital Xi'an Jiaotong University
LanZhou University; Henan Cancer Hospital; Shaanxi Provincial People's Hospital; Henan Provincial People's Hospital and other collaborators

Recruiting

Sodium Bicarbonate Ringer's Solution for Preventing and Treating Hyperlactacidemia During Hepatectomy

Hyperlactacidemia

China
Bial - Portela C S.A.

Completed

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

Epilepsy

United Kingdom
Chang Gung Memorial Hospital

Completed

Long-Term Lead Chelation Therapy and Progressive Renal Insufficiency

Urologic Disease

China
Michael C Roarke, MD

Completed

Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

Multiple Myeloma

United States
Pharma VAM

Unknown

Clinical Study in the Treatment of Patients With COVID-19

COVID-19

Russian Federation
Bial - Portela C S.A.

Completed

Bioequivalence of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

Painful Diabetic Neuropathy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Epilepsy
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy

Portugal
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Sarcoma | Ovarian Cancer | Brain Tumor | Ototoxicity | Neuroblastoma | Liver Cancer | Central Nervous System Tumor | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

Canada, United States, Australia
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Terminated

Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR) (MultiGFR)

Kidney Diseases | Renal Insufficiency, Chronic

France
Bial - Portela C S.A.

Completed

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Post Herpetic Neuralgia

Germany
Mt. Sinai Medical Center, Miami

Withdrawn

Prolonged Gadolinium Retention After MRI Imaging

Heavy Metal Toxicity

United States

3

Subscribe